Celon Pharma (WAR:CLN) Net Interest Margin (Bank Only) %


WAR:CLN Celon Pharma SA WAR:CLN
48 GF Score
Price zł19.80
GF Value zł22.91
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

WAR:CLN
48GF Score
Celon Pharma SA WAR:CLN
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł19.80 is trading 13.6% below its estimated GF Value™ of zł22.91. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: zł22.91 vs. price of zł19.80 (13.6% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for WAR:CLN

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.80
Price
zł22.91
GF Value